These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21648207)

  • 1. Omalizumab: a second look in severe persistent asthma: new adverse effects.
    Prescrire Int; 2011 Apr; 20(115):90-2. PubMed ID: 21648207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.
    Prescrire Int; 2007 Oct; 16(91):179-82. PubMed ID: 17926440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
    Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
    Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.
    Korn S; Thielen A; Seyfried S; Taube C; Kornmann O; Buhl R
    Respir Med; 2009 Nov; 103(11):1725-31. PubMed ID: 19515548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G; Renda T; Romeo P; Busceti MT; Maselli R
    Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab in children: a negative risk-benefit balance in severe persistent asthma.
    Prescrire Int; 2011 Apr; 20(115):92. PubMed ID: 21648208
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics.
    Pace E; Ferraro M; Bruno A; Chiappara G; Bousquet J; Gjomarkaj M
    J Asthma; 2011 May; 48(4):387-92. PubMed ID: 21391878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab: overview of pharmacology and efficacy in asthma.
    Ledford DK
    Expert Opin Biol Ther; 2009 Jul; 9(7):933-43. PubMed ID: 19527111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
    Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
    Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab as add-on therapy to inhaled steroids for asthma.
    Hadj Tahar A
    Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One year treatment with omalizumab is effective and well tolerated in Japanese Patients with moderate-to-severe persistent asthma.
    Ohta K; Yamamoto M; Sato N; Ikeda K; Miyamoto T
    Allergol Int; 2010 Jun; 59(2):167-74. PubMed ID: 20179417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study.
    Sthoeger ZM; Eliraz A; Asher I; Berkman N; Elbirt D
    Isr Med Assoc J; 2007 Jun; 9(6):472-5. PubMed ID: 17642399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab for severe asthma?
    Drug Ther Bull; 2006 Nov; 44(11):86-8. PubMed ID: 17089921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New drugs; omalizumab].
    Cohen AF; Dubois EA; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2871-2. PubMed ID: 17319219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma.
    Humbert M; Berger W; Rapatz G; Turk F
    Allergy; 2008 May; 63(5):592-6. PubMed ID: 18355388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.